Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Shares Outstanding (Weighted Average): 2014-2024

Historic Shares Outstanding (Weighted Average) for Ocular Therapeutix (OCUL) over the last 11 years, with Dec 2024 value amounting to $157.2 million.

  • Ocular Therapeutix's Shares Outstanding (Weighted Average) rose 11.59% to $174.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $174.0 million, marking a year-over-year increase of 11.59%. This contributed to the annual value of $157.2 million for FY2024, which is 97.96% up from last year.
  • As of FY2024, Ocular Therapeutix's Shares Outstanding (Weighted Average) stood at $157.2 million, which was up 97.96% from $79.4 million recorded in FY2023.
  • Over the past 5 years, Ocular Therapeutix's Shares Outstanding (Weighted Average) peaked at $157.2 million during FY2024, and registered a low of $71.4 million during FY2020.
  • Over the past 3 years, Ocular Therapeutix's median Shares Outstanding (Weighted Average) value was $79.4 million (recorded in 2023), while the average stood at $104.7 million.
  • Data for Ocular Therapeutix's Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 97.96% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Ocular Therapeutix's Shares Outstanding (Weighted Average) stood at $71.4 million in 2020, then rose by 7.31% to $76.6 million in 2021, then grew by 1.17% to $77.5 million in 2022, then increased by 2.46% to $79.4 million in 2023, then soared by 97.96% to $157.2 million in 2024.